

Enzymatic Differentiation of the Enantiotopic Hydroxymethyl Groups of Glycerol; Synthesis of Chiral Building Blocks

Detlev Breitgoff, Kurt Laumen, and Manfred P. Schneider*

FB 9 - Bergische Universität-GH-Wuppertal, D-5600 Wuppertal 1, Germany

The prochiral (**3b**), derived from glycerol, was transformed by enantioselective, enzymatic hydrolysis into the central chiral building block (*R*)-(**4**) of high enantiomeric purity, which was further elaborated into a variety of chiral building blocks with the glycerol skeleton.


Chiral glycerol derivatives [e.g. (*S*)- and (*R*)-2,2-dimethyl-1,3-dioxolane-4-methanol (**1**) or the corresponding aldehydes (*R*)- and (*S*)-(**2**)] have been used widely in the past as building blocks for the preparation of enantiomerically pure, biologically active molecules such as phospholipids,¹ PAF (platelet aggregation factor),² β -blockers,³ GABOB,^{4†} prostaglandins,⁵ brefeldin A,⁶ and many others.⁷ They are usually prepared from *D*-mannitol [(*S*)-(**1**) and (*R*)-(**2**)]⁸ and *L*-serine^{8,9} or ascorbic acid⁴ [(*R*)-(**1**) and (*S*)-(**2**)].

Surprisingly, glycerol itself has never been seriously considered as an alternative source of chiral building blocks with the glycerol skeleton. Differentiation of the two enantiotopic groups in prochiral glycerol derivatives [e.g. (**3**)] would in fact lead to chiral molecules [e.g. (*R*)-(**4**)] which could be transformed in *both* enantiomeric series by selective functional group manipulation (Scheme 1).

Hydrolytic enzymes are well known for their capability of enantiotopic group differentiation in prochiral diesters. On the basis of our previous experience¹⁰ they were the obvious choice for transformations such as (**3**) \rightarrow (*R*)-(**4**). Triglycerides, the cheapest and most logical substrates for these enzymatic transformations, proved to be unsuitable owing to the occurrence of rapid acyl migrations in the products. Clearly, the 2-position in glycerol had to be protected and compounds (**3**) were chosen as substrates in order to produce versatile chiral molecules like (*R*)-(**4**) with three chemically very different functional groups which could be manipulated selectively. In order to provide as much 'chirality' as possible per mole, the diacetate (**3b**) was preferred over derivatives with longer-chain fatty acids.

Glycerol can in fact be transformed easily *via* a known route¹¹ into 2-*O*-benzylglycerol (**3a**) which is simply acetylated to produce (**3b**) conveniently in several hundred gram quantities.


The enzymatic saponifications of (**3b**) [reaction (1)] were studied in the presence of several hydrolases using experimental conditions described previously.¹⁰ The results are summarized in Table 1. In addition to the desired monoacetates (*R*)- and (*S*)-(**4**) variable amounts of (**3a**) are formed which can, however, be easily removed by 'filtration' of the reaction mixture over silica gel.



Ideally, in a highly enantioselective transformation only one acetate group should be removed in order to obtain high optical and chemical yields. The best results in this respect were obtained with porcine pancreatic lipase (E.C.3.1.1.3) and a lipoprotein lipase (E.C.3.1.1.34), the latter producing (*R*)-(**4**) in very good chemical yield (75%) and remarkably

high optical purity (91% enantiomeric excess, e.e.) as determined by ¹H n.m.r. spectroscopy of the diastereoisomeric 'Mosher' esters.¹²

The acetate (*R*)-(**4**) {[α]_D²⁰ -13.2° (c 3, EtOH)} was transformed (H₂/Pd-C) into the known¹³ monoacetate (*R*)-(**5**) {[α]_D²² -9.2° (c 1.7, pyridine)} thereby confirming both the optical purity and the absolute configuration. Reaction with dihydropyran (*p*-MeC₆H₄SO₃H, room temp., 95%), followed by removal of the acetate group (K₂CO₃, MeOH, 95%) produced (*S*)-(**6**) {[α]_D²⁰ -8.7° (c 2, CHCl₃ + 1% EtOH),



Scheme 1. Reagents: i, H₂, Pd/C; ii, dihydropyran, *p*-MeC₆H₄SO₃H; iii, K₂CO₃, MeOH; iv, PhCOCl, pyridine; v, *p*-MeC₆H₄SO₃H, MeOH. THP = tetrahydropyran-2-yl.

† GABOB = (*R*)-4-amino-3-hydroxybutyric acid, an antiepileptic and hypotensive drug. See ref. 4.

Table 1. Enzymatic hydrolysis of (3b).

Enzyme ^a	% Conversion ^b	% Yield ^c	Abs. conf.	% E.e. ^d
<i>Candida cylindracea</i>	51	38	—	0
PLE (E.C.3.1.1.1)	51	43	S	29
<i>Mucor</i> sp.	45	42	R	35
<i>Chromobacterium viscosum</i>	52	52	R	29
Pancreatin	52	50	R	65
PPL (E.C.3.1.1.3)	50	40	R	60
PPL (E.C.3.1.1.3) ^e	50	40	R	80
Lipase (E.C.3.1.1.34)	53	75	R	91

^a Crude enzyme preparations were used. PLE = porcine liver esterase; PPL = porcine pancreatic lipase. ^b 50% conversion corresponds to the hydrolysis of one acetate group; ^c Isolated. ^d Enantiomeric excess, determined from ¹H n.m.r. spectra of the 'Mosher' esters,¹² ±3%. ^e +15% tetrahydrofuran cosolvent.

mixture of diastereoisomers}, an entry into the other enantiomeric series. (*S*)-(6) in turn was transformed *via* (*R*)-(7) into the known¹⁴ monobenzoate (*R*)-(8) {[α]_D²⁰ -13.3° (c 1.3, pyridine)}. The great utility of (*R*)-(4) and its synthetic versatility was further demonstrated by its transformation into the trityl, tosyl, and silyl derivatives (9)—(11) (Scheme 1). While most of these are oils, (10b) {[α]_D²⁰ -32° (c 1, CHCl₃ + 1% EtOH)} and (10c) {[α]_D²⁰ 9.3° (c 5, MeOH)} could be obtained with >97% e.e. by simple recrystallization.¹⁵

Obviously, starting from (*R*)-(4), a wide variety of useful chiral glycerol derivatives of both enantiomeric series can be made available by this method. To the best of our knowledge the experiments described constitute the first successful attempts to use glycerol itself for this purpose in a chemo-enzymatic approach. In view of the ready availability of large quantities of lipids (fats and oils) these preliminary results could allow their use for the preparation of chiral building blocks for organic syntheses.

We thank Bayer AG (Dr. J. Kurz) for n.m.r. spectra, and the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie for financial support.

Received, 16th May 1986; Com. 662

References

- E. Baer, J. Maurukas, and M. Russel, *J. Am. Chem. Soc.*, 1952, **74**, 152; E. Baer and H. C. Stancer, *ibid.*, 1952, **74**, 158; E. Baer and A. Kindler, *Biochemistry*, 1962, **1**, 518; E. Baer, in 'Biochemical Preparations,' ed. E. G. Ball, Wiley, New York, 1952.
- G. Hirth and R. Barner, *Helv. Chim. Acta*, 1982, **65**, 1059, and references cited therein.
- W. L. Nelson and T. Burke, Jr., *J. Org. Chem.*, 1978, **43**, 3641; D. E. McClure, E. L. Engelhardt, K. Mensler, S. King, W. Saadri, J. R. Huff, and J. J. Baldwin, *ibid.*, 1979, **44**, 1826.
- M. E. Jung and T. J. Shaw, *J. Am. Chem. Soc.*, 1980, **102**, 6304.
- G. Stork and T. Takahashi, *J. Am. Chem. Soc.*, 1977, **99**, 1275.
- T. Kitahara, K. Mori, and M. Matsui, *Tetrahedron Lett.*, 1979, 3021.
- Review: J. Jurczak, S. Pikul, and T. Bauer, *Tetrahedron*, 1986, **42**, 447.
- G. Hirth and W. Walther, *Helv. Chim. Acta*, 1985, **68**, 1863; H. O. L. Fischer and E. Baer, *ibid.*, 1934, **17**, 622; *J. Biol. Chem.*, 1939, **128**, 463.
- C. M. Lok, J. P. Ward, and D. A. van Dorp, *Chem. Phys. Lipids*, 1976, **16**, 115.
- M. Schneider, N. Engel, and H. Boensmann, *Angew. Chem.*, 1984, **96**, 52; *Angew. Chem. Int. Ed. Engl.*, 1984, **23**, 64; K. Laumen and M. Schneider, *Tetrahedron Lett.*, 1984, 5875; K. Laumen, E. H. Reimerdes, and M. Schneider, *ibid.*, 1985, 407; K. Laumen and M. Schneider, *ibid.*, 1985, 2073.
- N. Baggett, J. S. Brimacombe, A. B. Foster, M. Stacey, and D. H. Whiffen, *J. Chem. Soc.*, 1960, 2574.
- J. A. Dale, D. L. Dull, and H. S. Mosher, *J. Org. Chem.*, 1969, **34**, 2543.
- E. Baer and H. O. L. Fischer, *J. Am. Chem. Soc.*, 1945, **67**, 2031.
- C. Morpain and M. Tisserand, *J. Chem. Soc., Perkin Trans. 1*, 1979, 1379; E. Baer, J. B. Cushing, and H. O. L. Fischer, *Canad. J. Res.*, 1943, **21B**, 119.
- J. J. Baldwin, A. W. Raab, K. Mensler, B. H. Arison, and D. E. McClure, *J. Org. Chem.*, 1978, **43**, 4876.